This narrative review consolidates the available literature from animal and human studies describing the major clinical outcomes of SGLT2 inhibition in ASCVD and explores the potential mechanisms underpinning these effects with key findings presented. This evidence concerns the gene SLC5A2 and atherosclerosis.